Eloxx Pharmaceuticals (ELOX) vs Pliant Therapeutics (PLRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pliant Therapeutics is the larger company by market cap ($63.5 million vs $60.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | PLRX |
|---|---|---|
| Share price | $14.90 | $1.03 |
| Market cap | $60.12M | $63.47M |
| 1-day change | -1.88% | +2.51% |
| YTD return | — | -18.03% |
| 1-year return | — | -34.64% |
| 5-year return | — | -94.44% |
| P/E ratio (TTM) | 4.23 | — |
| EPS (TTM) | $3.52 | $-1.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.40 | $1.95 |
| 52-week low | $8.20 | $0.97 |
| Distance from 52-week high | -36.35% | -47.44% |
| Analyst consensus | none | none |
| Avg. price target upside | +156.80% | +95.12% |
| Average volume | 44.52K | 477.96K |
| Shares outstanding | 4.04M | 61.92M |
| Employees | 10 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Pliant Therapeutics
PLRX stock →Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
ELOX vs PLRX FAQ
Which is bigger, Eloxx Pharmaceuticals or Pliant Therapeutics?
Pliant Therapeutics (PLRX) is larger, with a market capitalization of $63.47M compared with $60.12M for Eloxx Pharmaceuticals (ELOX).
Are Eloxx Pharmaceuticals and Pliant Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Eloxx Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Pliant Therapeutics.